#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immune-mediated myositis Oesophageal adenocarcinoma Neurofibromatosis Neurotrophic keratopathy Multifocal motor neuropathy Alexander disease Philadelphia chromosome positive MELAS syndrome Hepatitis D Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Dilated cardiomyopathy Metabolic disorder Lung adenocarcinoma Breast cancer metastatic Oesophageal adenocarcinoma stage III More trials…

    Learn about Rare Diseases

    Pleural mesothelioma malignant – Life with Disease Cholangitis sclerosing – Basic Information Atypical haemolytic uraemic syndrome – Treatment Retinitis pigmentosa – Life with Disease Gaucher’s disease type III Familial amyotrophic lateral sclerosis – Diagnostics Loeys-Dietz syndrome – Treatment Pemphigus – Diagnostics Thrombotic thrombocytopenic purpura – Treatment Systemic sclerosis pulmonary – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gadoteridol Vibozilimod Glutathione Fitusiran Mebendazole Propranolol Allo-647 AGA2118 Ucp2 Sulfamethizole VINBLASTINE Danicamtiv Ephedrine Hydrochloride F44/10 Zofenopril Calcium Quavonlimab Baricitinib Galunisertib Op-1250 Mosaic Hbcoreag More therapies…

    Learn about Your Condition

    Melanoma recurrent Lung disorder Habitual abortion Naevoid melanoma Infertility Supraventricular tachycardia Affective disorder CADASIL Arteriosclerosis Thyroid cancer metastatic Colorectal adenoma Transferrin decreased Vomiting Pulmonary vascular disorder Chronic fatigue syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HIV infection

  • Study on Switching HIV Treatment to Dolutegravir/Lamivudine in Patients Aged 50+ with Virologic Suppression

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Dolutegravir Sodium
    • Lamivudine
    • Bictegravir
    Austria Belgium France Germany Italy The Netherlands +2

  • Study on the Effectiveness and Safety of Lamivudine, Dolutegravir Sodium, Cabotegravir, and Rilpivirine for Adults with HIV-1 Who Have Not Taken Antiretroviral Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Dolutegravir Sodium
    • Lamivudine
    • Cabotegravir
    France Germany Italy Spain

  • Study on the Effects of GSK4004280 and GSK4011499 in Adults with HIV Infections

    Not recruiting

    2 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Gsk4004280
    • Gsk4011499
    France Germany Italy Spain

  • Study on the Effects of GSK3739937 for Adults with HIV-1 Who Have Not Yet Received Treatment

    Not recruiting

    2 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Gsk3739937
    Greece Italy Poland Spain

  • Study Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Dolutegravir Sodium
    • Lamivudine
    • Bictegravir
    Belgium Denmark France Germany Greece Ireland +5

  • Study on the Effectiveness of Rilpivirine-Based Treatment for HIV Patients with Metabolic Liver Disease Using Dolutegravir, Rilpivirine, and Emtricitabine/Tenofovir Combination

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Dolutegravir Sodium
    • Rilpivirine Hydrochloride
    • Tenofovir Disoproxil Fumarate
    Spain
Previous Page
1 … 9 10 11 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!